Follow-on Biologics
Back to the Future with Biobetters
“Follow-on Biologics” encompasses both Biosimilars and Biobetters. Biosimilars are essentially newly manufactured versions of formerly patent protected biologics that will be marketed by competing developers. Biobetters are products which may carry the same therapeutic indication and work on similar targets as those previously approved novel biologic therapeutics. however, biobetters are differentiated by unique characteristics which convey superior clinical efficacy. This may be through attributes such as reduced dose, extended half-life, convenient dosage formulation and increased safety. Since biobetters have mutations or other modifications, they are new compositions of matter, they require new clinical trials and are usually patent protected.
A key attribute for Biobetters is to demonstrate superior therapeutic value. BioAtla’s powerful protein engineering platform for generation of Biobetters will break the barrier for next generation molecules.
A key attribute of a Biobetter is superior performance as a therapeutic. BioAtla provides a wide array of technologies for generating these next generation molecules that are differentiated from older lead molecules and provide powerful intellectual property protection. BioAtla’s antibody discovery technologies are rapid and allow comprehensive eptitope coverage, while remaining cost-effective.
BioAtla’s proprietary Mirac™ protein platform enables generation of a wide array of novel Biobetter molecules that deliver benefits such as reduction or elimination of negative on-target effects that are intractable using traditional technologies. Our antibody engineering capabilities also include novel antibody fragment generation and improvement, as well as enhancing diversity, expression and affinity of protein binding mimics.
Improving antibody conjugation for improved efficacy is a snap with BioAtla’s protein engineering that eliminates undesired sites, as well as introducing new linking sites that preserve molecule function.
These are just a few of the many ways that BioAtla’s expanding platform of technologies can be applied to create Biobetter molecules. Call us today to explore the possibilities.
BENEFITS:
Increased safety Access novel epitopes Improve conjugation Improve Fc effector function Novel and/or enhanced functionality